1. A CMV donor-positive/recipient-negative (D+/R-) kidney transplant recipient is being planned for CMV prevention. The program can offer either universal valganciclovir prophylaxis or PCR-guided pre-emptive therapy. Integrating the recipient's risk category with the trade-offs of each strategy, which plan is most defensible and why?
A) Pre-emptive therapy alone, because D+/R- recipients have pre-existing CMV immunity that limits replication between surveillance intervals
B) No intervention with surveillance only, because D+/R- carries the lowest infection risk
C) Universal valganciclovir prophylaxis, because D+/R- is the highest-risk category and prophylaxis most reliably prevents early end-organ disease, accepting the trade-off of possible late-onset CMV after discontinuation
D) Letermovir prophylaxis, because it is the standard agent for D+/R- solid organ recipients and covers HSV/VZV simultaneously
E) Pre-emptive foscarnet, because it avoids the myelosuppression of valganciclovir and needs no surveillance infrastructure
ANSWER: C
Rationale:
This requires integrating the serostatus matrix with the comparative logic of the two prevention strategies. Option C is correct: D+/R- is the highest-risk combination (50-80% infection, 20-30% end-organ disease without prophylaxis) because the seronegative recipient lacks CMV-specific memory and receives a virus-bearing graft; universal valganciclovir prophylaxis most reliably prevents early disease, with the recognized trade-off of late-onset CMV emerging after the drug is stopped.
Option A: Option A is incorrect: D+/R- recipients have NO pre-existing CMV immunity — that is precisely why they are highest-risk.
Option B: Option B is incorrect: D+/R- is the highest-, not lowest-, risk category (D-/R- is lowest), so surveillance-only is inadequate.
Option D: Option D is incorrect: letermovir is used for prophylaxis in seropositive HSCT recipients, not as standard SOT D+/R- prophylaxis, and it has no HSV/VZV activity.
Option E: Option E is incorrect: pre-emptive therapy inherently requires reliable PCR surveillance, and foscarnet is not a first-line prophylactic agent given its nephrotoxicity and infusion burden.
2. A CMV-seropositive allogeneic HSCT recipient is started on letermovir prophylaxis from day 0. The transplant team, reasoning from letermovir's mechanism, anticipates a specific coverage gap that must be addressed separately. Which gap follows directly from how letermovir works?
A) Letermovir inhibits only the CMV terminase complex, so it provides no activity against HSV or VZV; separate HSV/VZV prophylaxis (for example, acyclovir) is required
B) Letermovir inhibits the CMV DNA polymerase, so it will select rapidly for UL54 cross-resistant HSV
C) Letermovir suppresses the marrow, so granulocyte support must be added during prophylaxis
D) Letermovir covers HSV and VZV but not CMV, so an anti-CMV agent must be added
E) Letermovir's terminase inhibition extends to all herpesviruses, so no additional antiviral coverage is needed
ANSWER: A
Rationale:
This integrates the terminase mechanism with the practical consequence for herpesvirus coverage. Option A is correct: letermovir acts specifically on the CMV terminase complex (UL56/UL89/UL51), a CMV-specific packaging enzyme, and has no activity against HSV or VZV; because HSCT recipients are also at risk for HSV/VZV reactivation, separate prophylaxis such as acyclovir must be provided.
Option B: Option B is incorrect: letermovir does not inhibit the DNA polymerase and does not act on HSV at all, so UL54-mediated HSV cross-resistance is not the issue.
Option C: Option C is incorrect: letermovir is notably free of myelosuppression — that is a chief advantage in HSCT, not a gap.
Option D: Option D is incorrect: letermovir's whole purpose is CMV prophylaxis; it does cover CMV and does not cover HSV/VZV.
Option E: Option E is incorrect: terminase inhibition is CMV-specific and does not extend to other herpesviruses. The mechanism that makes letermovir CMV-specific is exactly what creates the HSV/VZV gap.
3. An HSCT recipient with profound neutropenia has CMV disease that is failing ganciclovir, and genotyping shows an isolated UL97 mutation with wild-type UL54. Considering both the resistance mechanism and the patient's marrow status, why is foscarnet the rational choice over escalating ganciclovir?
A) Foscarnet is activated more efficiently by UL97 than ganciclovir, overcoming the mutation
B) Foscarnet is myelosuppressive but less so than ganciclovir, so it is tolerable in neutropenia
C) Higher-dose ganciclovir would overcome the UL97 mutation, but foscarnet is chosen only for convenience
D) The UL97 mutation impairs ganciclovir activation while wild-type UL54 keeps the polymerase foscarnet-susceptible, and foscarnet's lack of myelosuppression suits the neutropenic patient, though its nephrotoxicity and electrolyte wasting must be managed
E) Foscarnet and ganciclovir share the same resistance pathway, so neither will work and cidofovir is mandatory
ANSWER: D
Rationale:
This integrates the activation/resistance mechanism with the toxicity profile to justify agent selection. Option D is correct: an isolated UL97 mutation impairs the phosphorylation that activates ganciclovir, so dose escalation cannot restore efficacy, while wild-type UL54 means the polymerase target remains susceptible to foscarnet, which requires no activation; additionally foscarnet is not myelosuppressive, an advantage in a neutropenic HSCT patient — accepting that its nephrotoxicity and electrolyte wasting (hypocalcemia, hypomagnesemia, hypokalemia) require active management.
Option A: Option A is incorrect: foscarnet requires no UL97 activation at all; it does not use that enzyme.
Option B: Option B is incorrect: foscarnet's signature toxicities are renal and electrolyte, not myelosuppression.
Option C: Option C is incorrect: raising the dose of a drug the virus cannot activate does not work.
Option E: Option E is incorrect: foscarnet and ganciclovir do not share an activation pathway, and with wild-type UL54 foscarnet is expected to work.
4. A patient with CMV disease has progressed through ganciclovir and then foscarnet. Repeat genotyping now shows combined UL97 and UL54 mutations. Integrating what each gene controls with the resulting cross-resistance, which assessment and plan is most appropriate?
A) Only ganciclovir activation is affected; resume full-dose ganciclovir with confidence
B) This represents high-level multidrug resistance because UL54 alters the shared polymerase target; management integrates combination foscarnet plus ganciclovir at reduced doses, reduction of immunosuppression, and consideration of maribavir, whose UL97 binding site differs from common resistance codons
C) The UL54 mutation guarantees letermovir efficacy, so switch to letermovir monotherapy for treatment
D) Cidofovir is always fully active against any UL54 mutation, so it is a guaranteed cure
E) Because two genes are mutated, no pharmacological option remains and only supportive care is appropriate
ANSWER: B
Rationale:
This requires integrating gene function, cross-resistance, and a multi-pronged management plan. Option B is correct: UL97 mutations impair ganciclovir activation and UL54 mutations alter the DNA polymerase that ganciclovir, foscarnet, and cidofovir share, so combined mutations produce high-level multidrug resistance; rational management integrates combination foscarnet plus ganciclovir at reduced doses, reduction of immunosuppression to restore immune control, and consideration of maribavir, which inhibits UL97 at a site distinct from the common ganciclovir-resistance codons.
Option A: Option A is incorrect: with a UL54 mutation the problem is not limited to activation, and ganciclovir cannot be relied upon.
Option C: Option C is incorrect: letermovir is a prophylactic agent with a low resistance barrier and is not the treatment for established multidrug-resistant disease; UL54 status does not confer letermovir efficacy.
Option D: Option D is incorrect: specific UL54 substitutions can confer cidofovir cross-resistance, so it is not guaranteed.
Option E: Option E is incorrect: combination therapy, immunosuppression reduction, and investigational agents remain options.
5. An allogeneic HSCT recipient develops profuse diarrhea three weeks post-transplant. The differential is gut graft-versus-host disease (GVHD) versus CMV colitis. Blood CMV PCR is negative. Integrating the diagnostic limitation with the opposing treatments these two conditions require, what is the correct next step before escalating corticosteroids?
A) Empirically escalate corticosteroids for presumed GVHD, since a negative blood PCR excludes CMV colitis
B) Start high-dose corticosteroids and ganciclovir together and forgo tissue sampling
C) Treat for CMV colitis with ganciclovir alone and assume GVHD is excluded
D) Repeat blood CMV PCR daily and withhold all treatment until it becomes positive
E) Perform colonoscopy with biopsy for histology and CMV immunostaining, because a negative blood PCR does not exclude CMV colitis and escalating steroids for misdiagnosed CMV would worsen it
ANSWER: E
Rationale:
This integrates the false-negative limitation of blood PCR with the fact that GVHD and CMV colitis require opposite treatments. Option E is correct: CMV can replicate within colonic mucosa without producing detectable viremia, so a negative blood PCR cannot exclude CMV colitis; because GVHD requires intensified immunosuppression while CMV colitis requires antiviral therapy and reduced immunosuppression, tissue diagnosis by colonoscopic biopsy (owl-eye inclusions, CMV immunostaining) is essential before escalating corticosteroids, which would worsen unrecognized CMV.
Option A: Option A is incorrect: this enacts the central error — treating a negative blood PCR as exclusion.
Option B: Option B is incorrect: blindly combining steroids and ganciclovir without tissue diagnosis risks harming the patient if GVHD is absent and steroids worsen CMV.
Option C: Option C is incorrect: assuming CMV without tissue confirmation can miss GVHD and is not the standard approach.
Option D: Option D is incorrect: passively waiting delays care in a deteriorating patient; antiviral therapy should not be withheld solely while awaiting tissue results in a compatible presentation.
6. In EBV-positive PTLD, reduction of immunosuppression is the first intervention and rituximab is added if that is insufficient. Integrating EBV latency biology with this hierarchy, what is the mechanistic reason reduction of immunosuppression is positioned first?
A) Reduction of immunosuppression lowers drug levels so rituximab can penetrate lymphoid tissue more effectively
B) Reduction of immunosuppression activates EBV thymidine kinase, finally allowing ganciclovir to work
C) PTLD arises when immunosuppression cripples EBV-specific cytotoxic T-cell surveillance, so reducing immunosuppression restores that surveillance and can control the proliferation at its root, with rituximab depleting the CD20+ B-cell reservoir when this is inadequate
D) Reduction of immunosuppression directly lyses CD20+ B cells, making rituximab redundant
E) Rituximab cannot be given until immunosuppression is fully withdrawn because the two are chemically incompatible
ANSWER: C
Rationale:
This integrates the immunological pathogenesis of PTLD with the rationale for the treatment sequence. Option C is correct: PTLD is driven by EBV-transformed B cells proliferating because immunosuppression has disabled EBV-specific cytotoxic T-cell surveillance; restoring that surveillance by reducing immunosuppression addresses the root cause and produces responses in early polymorphic disease, while rituximab (anti-CD20) depletes the B-cell reservoir when reduction alone is insufficient.
Option A: Option A is incorrect: the sequence is driven by immune restoration, not by improving rituximab tissue penetration.
Option B: Option B is incorrect: latently infected B cells do not express viral thymidine kinase, so ganciclovir remains ineffective regardless of immunosuppression changes.
Option D: Option D is incorrect: reducing immunosuppression does not directly lyse B cells; it restores T-cell surveillance.
Option E: Option E is incorrect: there is no chemical incompatibility, and rituximab is given alongside reduced immunosuppression, not after full withdrawal. Aggressive monomorphic PTLD additionally requires R-CHOP.
7. An allogeneic HSCT recipient has biopsy/BAL-confirmed CMV pneumonitis. The team designs a regimen of IV ganciclovir plus IVIG and also reduces immunosuppression where feasible. Integrating the lethality of this manifestation with the rationale for each component, which explanation is correct?
A) CMV pneumonitis is the most lethal CMV manifestation in allogeneic HSCT; ganciclovir provides direct antiviral activity, IVIG adds CMV-specific neutralizing antibody at the alveolar surface (combination outperforms antiviral monotherapy in observational data), and reducing immunosuppression restores host antiviral immunity
B) The regimen relies on IVIG as the sole antiviral, with ganciclovir added only to prevent bacterial superinfection
C) Reducing immunosuppression is contraindicated in CMV pneumonitis because it accelerates viral replication, so only drugs should be used
D) IVIG works by inhibiting the CMV DNA polymerase, making ganciclovir redundant
E) CMV pneumonitis is a benign, self-limited condition, so aggressive combination therapy is unnecessary
ANSWER: A
Rationale:
This integrates disease severity with the distinct contribution of each treatment element. Option A is correct: CMV pneumonitis carries 30-50% mortality in allogeneic HSCT even with therapy; ganciclovir supplies direct antiviral activity, IVIG contributes CMV-specific neutralizing antibody at the pulmonary mucosal surface (combination therapy outperforms antiviral monotherapy in observational HSCT data), and reducing immunosuppression where feasible helps restore the host antiviral response.
Option B: Option B is incorrect: ganciclovir, not IVIG, is the antiviral backbone; IVIG is an immunologic adjunct.
Option C: Option C is incorrect: reducing immunosuppression is an important adjunct, not a contraindication, in this setting.
Option D: Option D is incorrect: IVIG is neutralizing antibody, not a polymerase inhibitor, and does not replace ganciclovir.
Option E: Option E is incorrect: CMV pneumonitis is the most lethal CMV manifestation in HSCT, the opposite of benign. Diagnosis itself requires BAL because blood CMV PCR can be negative.
8. A pharmacologist explains why brincidofovir was engineered as a lipid conjugate of cidofovir rather than as a new pharmacophore. Integrating cidofovir's mechanism of nephrotoxicity with brincidofovir's cellular pharmacology, which explanation is correct?
A) Brincidofovir abandons the cidofovir mechanism entirely, using glomerular filtration enhancement to clear virus faster
B) Brincidofovir is more avidly transported by OAT1 than cidofovir, concentrating it in the tubule for greater potency
C) Brincidofovir requires viral kinase activation that cidofovir lacks, which both narrows its spectrum and spares the kidney
D) Cidofovir nephrotoxicity stems from OAT1-mediated uptake and accumulation in proximal tubular cells; the lipid conjugate of brincidofovir enters cells by lipid endocytosis, bypassing OAT1 so the proximal tubule is spared, while intracellular phospholipases release active cidofovir diphosphate, preserving the antiviral mechanism
E) Brincidofovir is renally inert because it is excreted unchanged in bile and never enters any cell
ANSWER: D
Rationale:
This integrates the transporter basis of cidofovir toxicity with the rational design that retains efficacy while removing the liability. Option D is correct: cidofovir is taken up into proximal tubular cells by OAT1, where accumulation drives nephrotoxicity; attaching a lipid group lets brincidofovir enter cells via lipid endocytosis, bypassing OAT1 and sparing the tubule, while intracellular phospholipases liberate active cidofovir diphosphate so the polymerase-inhibiting mechanism is preserved.
Option A: Option A is incorrect: brincidofovir delivers the same active cidofovir species; it does not abandon the mechanism.
Option B: Option B is incorrect: the design AVOIDS OAT1 uptake rather than enhancing it.
Option C: Option C is incorrect: like cidofovir, brincidofovir is activated by host (not viral) kinases, which preserves broad dsDNA-virus coverage.
Option E: Option E is incorrect: brincidofovir must enter cells to act; the point is the route of entry, not exclusion from cells. Despite the renal advantage, a phase 3 adenovirus trial did not show a survival benefit.
9. A kidney transplant program monitors plasma BK viral load and, on detecting a rising load before nephropathy is established, reduces immunosuppression pre-emptively. Integrating the surveillance rationale with the immune balance unique to a kidney allograft, which statement best captures the strategy and its central tension?
A) The strategy is to escalate immunosuppression on rising BK load to protect the graft from rejection, since BK is harmless
B) Serial BK PCR enables pre-emptive reduction of immunosuppression to restore BK-specific T-cell control before nephropathy develops; the central tension is that the same reduction that clears BK also raises the risk of allograft rejection, so it must be titrated carefully
C) The strategy relies on starting ganciclovir at a viral-load threshold, because BK responds reliably to it
D) Letermovir is begun at the threshold because BK shares the CMV terminase target
E) Surveillance is pointless because BK nephropathy cannot be influenced by immunosuppression changes
ANSWER: B
Rationale:
This integrates pre-emptive monitoring with the rejection-versus-virus balance specific to kidney transplantation. Option B is correct: serial plasma BK PCR allows immunosuppression to be reduced pre-emptively, restoring BK-specific cytotoxic T-cell control before nephropathy is established; the central tension is that reducing immunosuppression to clear BK simultaneously increases the risk of allograft rejection, so the reduction must be carefully titrated against graft function.
Option A: Option A is incorrect: escalating immunosuppression worsens BK replication, and BK is not harmless to the graft.
Option C: Option C is incorrect: ganciclovir is not active against BK virus.
Option D: Option D is incorrect: letermovir is CMV-specific (the CMV terminase) and has no role against BK.
Option E: Option E is incorrect: immunosuppression reduction is precisely the effective lever in BK nephropathy. Low-dose cidofovir or leflunomide are reserved for refractory cases on limited evidence.
10. A patient on natalizumab develops PML. The team plans to stop natalizumab and use plasma exchange to accelerate its clearance. Integrating why antivirals fail in PML with the consequences of rapidly restoring CNS immune surveillance, which statement best captures the full reasoning?
A) Cidofovir should be started immediately because it reliably clears JC virus, and plasma exchange is unnecessary
B) Natalizumab should be continued to suppress the inflammation that drives PML, since immune cells worsen the disease
C) The goal is to deepen immunosuppression so JC virus replication slows, accepting that PML is otherwise untreatable
E) Because no antiviral is effective against JC virus, recovery depends on restoring JC virus-specific T-cell surveillance; discontinuing natalizumab (hastened by plasma exchange) achieves this, but rapid return of lymphocyte CNS trafficking can precipitate immune reconstitution inflammatory syndrome (IRIS), which must be anticipated and managed
ANSWER: E
Rationale:
This integrates antiviral futility in PML with the double-edged nature of immune restoration. Option E is correct: no antiviral (cidofovir included) has proven effective against JC virus, so control depends on restoring JC virus-specific cytotoxic T-cell surveillance; stopping natalizumab — accelerated by plasma exchange — restores lymphocyte trafficking into the CNS, but that rapid return of immune cells can trigger IRIS against PML lesions, a complication that must be anticipated and managed (sometimes with corticosteroids).
Option A: Option A is incorrect: cidofovir has failed to show benefit in PML.
Option B: Option B is incorrect: continuing natalizumab perpetuates the loss of CNS surveillance that allowed PML.
Option C: Option C is incorrect: deepening immunosuppression worsens PML by further suppressing the needed T-cell response.
Option D: Option D is incorrect: corticosteroids do not inhibit JC virus polymerase and are not curative; they are used to temper IRIS. The natalizumab mechanism — blocking alpha-4 integrin (VLA-4) lymphocyte trafficking — is exactly why withdrawal restores, and can over-restore, CNS immunity.
11. An asymptomatic HSCT recipient has a very high, stable plasma HHV-6 DNA level unchanged by a trial of ganciclovir. Integrating the biology of chromosomal integration with the management decision, what is the correct course?
A) Recognize likely inherited chromosomally integrated HHV-6 (iciHHV-6): confirm by detecting HHV-6 DNA in hair follicle cells, and if confirmed in an asymptomatic patient, avoid committing to antiviral therapy, since the high plasma load reflects integrated genome in every cell rather than active replication
B) Diagnose active HHV-6 encephalitis and intensify ganciclovir, since the load is very high
C) Conclude the assay is contaminated and simply repeat the plasma PCR to resolve the question
D) Switch to foscarnet at full dose, since a treatment-unresponsive load proves drug resistance
E) Attribute the result to CMV cross-reactivity and treat for CMV instead
ANSWER: A
Rationale:
This integrates integration biology, the confirmatory test, and the resulting treatment decision. Option A is correct: a very high, stable, treatment-unresponsive plasma HHV-6 load in an asymptomatic patient suggests iciHHV-6, in which the viral genome is integrated into host chromosomes and present in every nucleated cell; confirmation is by detecting HHV-6 DNA in hair follicle cells, and recognizing it prevents unnecessary, toxic antiviral therapy for what is a carrier state, not active disease.
Option B: Option B is incorrect: HHV-6 encephalitis is a clinical CNS syndrome diagnosed by CSF PCR, and this patient is asymptomatic.
Option C: Option C is incorrect: a reproducible high load is not contamination, and repeating plasma PCR cannot distinguish integration from viremia.
Option D: Option D is incorrect: a treatment-unresponsive load here reflects integration, not drug resistance, and switching agents is unwarranted.
Option E: Option E is incorrect: the HHV-6 assay is specific and CMV does not cross-react in this way. The decisive value is in not treating an integrated carrier state as active infection.
12. A CMV-seropositive HSCT recipient maintained on tacrolimus is started on letermovir prophylaxis. Integrating letermovir's effect on drug-metabolizing enzymes with calcineurin inhibitor pharmacology, what should the team anticipate and do?
A) Letermovir induces tacrolimus metabolism, so the tacrolimus dose must be increased and levels will fall
B) Letermovir has no metabolic interaction with calcineurin inhibitors, so no dose change or monitoring is needed
C) Letermovir is a moderate CYP3A4 inhibitor and will raise tacrolimus concentrations; the team should reduce the tacrolimus dose at letermovir initiation and monitor trough levels closely during the first weeks of combined therapy
D) Letermovir chelates tacrolimus in the gut, lowering its absorption, so tacrolimus should be given intravenously instead
E) Letermovir's interaction is limited to mycophenolate through additive myelosuppression, not to tacrolimus
ANSWER: C
Rationale:
This integrates letermovir's CYP3A4 inhibition with the narrow therapeutic index of calcineurin inhibitors. Option C is correct: letermovir is a moderate inhibitor of CYP3A4 (and CYP2C8) and increases tacrolimus and cyclosporine concentrations (tacrolimus by roughly 40-45%); at letermovir initiation the calcineurin inhibitor dose should be reduced and trough levels monitored closely during the first weeks to avoid toxicity.
Option A: Option A is incorrect: letermovir inhibits rather than induces CYP3A4, so tacrolimus levels rise, not fall.
Option B: Option B is incorrect: there is a clinically significant interaction requiring dose adjustment and monitoring.
Option D: Option D is incorrect: the interaction is metabolic (CYP3A4 inhibition), not gut chelation, and switching to IV does not address it.
Option E: Option E is incorrect: while valganciclovir plus mycophenolate produces additive myelosuppression, letermovir's defining interaction here is CYP3A4-mediated elevation of calcineurin inhibitor levels. This metabolic interaction is distinct from letermovir's clean (non-myelosuppressive) toxicity profile.
13. Two scenarios are presented: (1) an HIV patient on new antiretroviral therapy whose treated CMV retinitis paradoxically worsens as the CD4 count rises, and (2) a transplant recipient in whom reducing immunosuppression to manage one infection unmasks simultaneous EBV, adenovirus, and HHV-6 reactivations. Integrating both, which single principle unifies them?
A) Both reflect antiviral drug resistance emerging during therapy
B) Both are manifestations of immune reconstitution: as suppressed immunity recovers, the returning immune response drives paradoxical inflammation against residual antigen (CMV IRIS) or unmasks previously controlled subclinical infections (transplant viral unmasking) — the same restored immunity that controls infection can transiently worsen or reveal disease
C) Both are explained by direct drug toxicity to the affected organs, unrelated to immune status
D) Both indicate primary treatment failure requiring a switch to second-line antivirals
E) Both occur only in HIV and have no analog in the transplant setting
ANSWER: B
Rationale:
This final integration question ties the module's central theme together across two contexts. Option B is correct: both scenarios stem from immune reconstitution — in HIV-associated CMV IRIS, recovering CD4+ T cells mount inflammation against residual CMV antigen despite good virologic control, causing paradoxical worsening; in transplantation, reducing immunosuppression to treat one infection allows T-cell recovery that unmasks previously subclinical EBV, adenovirus, or HHV-6 infections. The unifying principle is that restoring immunity, while therapeutic, can transiently worsen or reveal infection.
Option A: Option A is incorrect: resistance is not the mechanism; virologic markers typically improve in IRIS.
Option C: Option C is incorrect: the phenomenon is immune-mediated, not direct drug toxicity.
Option D: Option D is incorrect: improving virologic markers argue against treatment failure.
Option E: Option E is incorrect: the principle applies across both HIV and transplant settings, which is the entire point of integrating the two scenarios. Recognizing this prevents misclassifying IRIS as failure and anticipates polyviral unmasking when immunosuppression is reduced.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.